Document Detail


Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.
MedLine Citation:
PMID:  22725625     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Since the first discovery of an inverse correlation between high-density lipoprotein-cholesterol (HDL-C) levels and coronary heart disease in the 1950s the life cycle of HDL, its role in atherosclerosis and the therapeutic modification of HDL-C levels have been major research topics. The Framingham study and others that followed could show that HDL-C is an independent cardiovascular risk factor and that the increase of HDL-C of only 10 mg·L(-1) leads to a risk reduction of 2-3%. While statin therapy and therefore low-density lipoprotein-cholesterol (LDL-C) reduction could lower coronary heart disease considerably; cardiovascular morbidity and mortality still occur in a significant portion of subjects already receiving therapy. Therefore, new strategies and therapies are needed to further reduce the risk. Raising HDL-C was thought to achieve this goal. However, established drug therapies resulting in substantial HDL-C increase are scarce and their effect is controversial. Furthermore, it is becoming increasingly evident that HDL particle functionality is at least as important as HDL-C levels since HDL particles not only promote reverse cholesterol transport from the periphery (mainly macrophages) to the liver but also exert pleiotropic effects on inflammation, haemostasis and apoptosis. This review deals with the biology of HDL particles, the established and future therapeutic options to increase HDL-C and discusses the results and conclusions of the most important studies published in the last years. Finally, an outlook on future diagnostic tools and therapeutic opportunities regarding coronary artery disease is given.
Authors:
K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Related Documents :
18085245 - Effects of volatile anesthetics on carotid body response to hypoxia in animals.
7458065 - Comparison of sputum and lung asbestos body counts in former asbestos workers.
25363785 - Efficacy and acceptability of the new oral phosphate binder lenziaren(®) in healthy cat...
12907705 - Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia...
7745155 - Milk production and intake of lactating cows fed grass silage with protein and energy s...
23329815 - Astrocytic leptin-receptor knockout mice show partial rescue of leptin resistance in di...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  British journal of pharmacology     Volume:  167     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-22     Completed Date:  2013-03-25     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1177-94     Citation Subset:  IM    
Copyright Information:
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.
Affiliation:
Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiovascular Diseases / drug therapy*,  metabolism
Cholesterol, HDL / metabolism*
Fibric Acids / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Niacin / therapeutic use
Risk Reduction Behavior
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Fibric Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 59-67-6/Niacin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute pyelonephritis and associated complications during pregnancy in 2006 in US hospitals.
Next Document:  Association of CFU-Mk with total colony-forming unitsin thawed cord blood units.